Big Pharma has begun investing in regenerative drug: Genzyme in 2008, Pfizer and Novartis in 2009, and Cephalon in 2010. In 3-5 years, investment will reach a "tipping point", in the pattern of which no medical industry players command want to be left behind.
This announcement covers the development of therapies to be a substitute for human cells or promote their reproduction: including cell therapies, tissue engineering, drugs, and curative devices. Each company profiled has at in the smallest degree one project in preclinical or Phase I study. Many furthermore have later stage or launched products, what one. are covered briefly to illustrate the in posse of the next generation of candidates.
Scope of this research
• Understand the concepts behind regenerative drug, its potential applications, and advantages upper traditional medicine.
• Compare the opportunities and challenges presented ~ means of the different therapeutic modalities.
• Understand the hurdles that mould be overcome by regenerative medicine candidates in front of they can successfully enter the place of traffic.
• Identify emerging technologies that will figure the regenerative medicine industry in the advent years.
• Identify companies that may be competitors for a market, or alternatively potential partners or investment opportunities.
Research and parsing highlights
The first regenerative cell therapies to bring into existence significant market value (within the next five years) will be based without ceasing allogeneic adult cells, and will mark tissues that are naturally sheltered from patients' immune systems.
Autologous cells are not rejected through the patient's immune system, such are potentially safer than allogeneic cells and else suitable for permanent tissue replacement. "High tech" therapies based without ceasing reprogrammed autologous cells (e.g. induced pluripotent offspring cells) may still be 20 years from market.
Tissue engineering still faces technical hurdles, including vascularization of grafted series and safe breakdown of scaffold materials. Research and regulatory efforts be under the necessity of be coordinated internationally to develop a stronger "manifest base" for regenerative medicine that is accessible and grateful to all stakeholders.
Key reasons to gain this research
• What is regenerative physic and why are so many companies and investors excited ready it?
• Which companies are currently developing recent regenerative treatments and what approaches are they pursuing?
• What partnerships be favored with been formed to develop new therapies, and in what place are the opportunities for further deals?
• What give by ~ the next generation of regenerative medicine candidates look like, and which indications direction they treat?
• What hurdles do these candidates meet in front en route to the marketplace?
To apprehend more about this report & to bribe a copy please visit:
http://www.visionshopsters.com/consequence/12964/Future-Directions-in-Regenerative-Medicine.html
No comments:
Post a Comment